相似文献
1
Reply: Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.
JACC CardioOncol. 2023 Dec 19;5(6):850. doi: 10.1016/j.jaccao.2023.10.003. eCollection 2023 Dec.
2
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.
JACC CardioOncol. 2023 Dec 19;5(6):848-849. doi: 10.1016/j.jaccao.2023.09.006. eCollection 2023 Dec.
3
Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
JACC CardioOncol. 2023 Jun 6;5(5):628-637. doi: 10.1016/j.jaccao.2023.04.004. eCollection 2023 Oct.
4
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
ESC Heart Fail. 2022 Jun;9(3):1914-1919. doi: 10.1002/ehf2.13897. Epub 2022 Mar 31.
5
Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.
J Clin Med. 2023 Feb 6;12(4):1278. doi: 10.3390/jcm12041278.
6
Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.
Acta Oncol. 2022 Jan;61(1):45-51. doi: 10.1080/0284186X.2021.1992010. Epub 2021 Oct 19.
7
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Cancer Treat Rev. 2021 Nov;100:102282. doi: 10.1016/j.ctrv.2021.102282. Epub 2021 Aug 18.
8
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
Breast Cancer Res Treat. 2021 Jul;188(1):149-163. doi: 10.1007/s10549-021-06192-w. Epub 2021 Apr 5.
9
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.
Int J Cardiol. 2022 Feb 15;349:134-137. doi: 10.1016/j.ijcard.2021.11.059. Epub 2021 Nov 27.
10
Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.
J Clin Med. 2022 Feb 5;11(3):847. doi: 10.3390/jcm11030847.
本文引用的文献
1
Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores.
JACC CardioOncol. 2023 Jun 6;5(5):628-637. doi: 10.1016/j.jaccao.2023.04.004. eCollection 2023 Oct.
2
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.
Eur Heart J. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674.
3
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Eur J Heart Fail. 2020 Nov;22(11):1945-1960. doi: 10.1002/ejhf.1920. Epub 2020 Aug 6.
Zotero 插件